Literature DB >> 22585233

Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome.

Sonali Wijetilleka1, Tina Scoble, Munther Khamashta.   

Abstract

PURPOSE OF REVIEW: To provide an update of recent insights into the pathogenesis, diagnosis and treatment of antiphospholipid syndrome (APS) from current literature. RECENT
FINDINGS: β2GPI was recently implicated in the pathogenesis of thrombosis. High titres of anti-β2GPI antibodies are present in patients with triple positivity which highlight its importance. Consensus guidelines have been published to standardise diagnostic assays and once implemented may yield more accurate diagnoses of APS. An 'aPL score' has been formulated to improve the detection and outcomes of patients. New oral anticoagulants, statins and concomitant therapy with warfarin and aspirin have been identified as potential novel therapeutic interventions for thrombotic APS. Advances in the pathogenesis of obstetric APS have occurred, such as the concept of redefining the syndrome as inflammatory and clearer identification of the roles of complement, β2GPI and annexin 5. Independent risk factors for pregnancy failure have been recognised and when combined with clinical and laboratory features may improve patient outcomes. Interventions involving adjusted doses of low molecular weight heparin in combination with aspirin have shown promising results from initial studies.
SUMMARY: Recent insights into the pathogenesis of APS have unveiled novel areas for treatment intervention. Diagnostic criteria and recommendations have been revised and formulated to provide consensus and standardisation for diagnosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22585233     DOI: 10.1097/BOR.0b013e328354ae8c

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  6 in total

1.  Antiphospholipid syndrome presenting as pulmonary thrombosis and pancreatitis in a young man.

Authors:  Sanat Phatak; Neelam Redkar; Meenakshi Amit Patil; Niteen D Karnik
Journal:  BMJ Case Rep       Date:  2012-12-12

Review 2.  Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?

Authors:  Guilherme R de Jesús; Gustavo Rodrigues; Nilson R de Jesús; Roger A Levy
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 3.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

4.  Identification of the binding site for fondaparinux on Beta2-glycoprotein I.

Authors:  Alexey Kolyada; Alfredo De Biasio; Natalia Beglova
Journal:  Biochim Biophys Acta       Date:  2013-06-25

5.  Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative.

Authors:  Emmanuel Coloma Bazán; Carolina Donate López; Pedro Moreno Lozano; Ricard Cervera; Gerard Espinosa
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 6.  Aspirin for prevention of preeclampsia in lupus pregnancy.

Authors:  Amelie M Schramm; Megan E B Clowse
Journal:  Autoimmune Dis       Date:  2014-03-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.